Limits...
Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials.

Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ - BMJ (2015)

Bottom Line: We compared relative risk differences using the Mantel-Haenszel random effects method to assess total respiratory adverse events, infectious respiratory adverse events, non-infectious respiratory adverse events, interstitial lung disease, and death.Findings suggested that there was no increased risk of lung disease in methotrexate treated patients with non-malignant inflammatory diseases.Given the limitations of the study, however, we cannot exclude a small but clinically important risk.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology, Galway University Hospitals, Galway, Republic of Ireland National University of Ireland Galway, Galway, Republic of Ireland drrichardconway@gmail.com.

Show MeSH

Related in: MedlinePlus

Fig 1 Flow of studies through review
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4358852&req=5

fig1: Fig 1 Flow of studies through review

Mentions: From the literature search 3188 citations were identified: 2968 from PubMed, 162 from the Cochrane central register of controlled trials, and 58 from Embase. Of the 3188 studies, only seven articles met the predefined inclusion criteria and were included in the meta-analysis (fig 1).


Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials.

Conway R, Low C, Coughlan RJ, O'Donnell MJ, Carey JJ - BMJ (2015)

Fig 1 Flow of studies through review
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4358852&req=5

fig1: Fig 1 Flow of studies through review
Mentions: From the literature search 3188 citations were identified: 2968 from PubMed, 162 from the Cochrane central register of controlled trials, and 58 from Embase. Of the 3188 studies, only seven articles met the predefined inclusion criteria and were included in the meta-analysis (fig 1).

Bottom Line: We compared relative risk differences using the Mantel-Haenszel random effects method to assess total respiratory adverse events, infectious respiratory adverse events, non-infectious respiratory adverse events, interstitial lung disease, and death.Findings suggested that there was no increased risk of lung disease in methotrexate treated patients with non-malignant inflammatory diseases.Given the limitations of the study, however, we cannot exclude a small but clinically important risk.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology, Galway University Hospitals, Galway, Republic of Ireland National University of Ireland Galway, Galway, Republic of Ireland drrichardconway@gmail.com.

Show MeSH
Related in: MedlinePlus